Skip to main content


  • ePoster presentation
  • Open Access

HAART restores the frequency of regulatory T cells (Tregs) among HIV/AIDS patients

  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 3,
  • 3,
  • 3 and
  • 1Email author
BMC Infectious Diseases201414 (Suppl 3) :E1

  • Published:


  • Immune Response
  • Cell Count
  • Viral Load
  • Positive Patient
  • Gradual Loss


Immunosuppression is the hallmark HIV infection associated with gradual loss of CD4+Tcells. The effector immune response is regulated by CD4+CD25+Foxp3+Tcells (Tregs). Enumeration of Tregs frequency showed equivocal results before and here we showed clearly their frequency by flowcytometry.


One hundred and eight individuals comprising of 71 HIV positive patients (44 patients undergoing HAART and 27 without HAART) and 37 HIV negative healthy controls. PBMCs were isolated and stained with CD4/FITC, CD25/APC, FoxP3/PE antibodies (BD Pharmingen) and analyzed for Tregs frequency by flowcytometer (BD FACS Calibur).


Our study showed that healthy controls had a Tregs frequency of 4.1%. When Tregs frequency analyzed among HIV/AIDS patients who are yet to receive HAART we found a significant reduction in Tregs population i.e. 1.2%. Encouragingly this deep plunge in Tregs population was found to be restored and surged upon HAART up to 12.6%. However, these changes in percentages did not alter based on their gender or age or absolute CD4 count of the study population.


HAART is known to decrease viral load and improve the patient’s CD4 cells count. Here we report that HAART has improved the Tregs frequency. It is yet to be known that the consequence of resurging Tregs during HIV/AIDS.

Authors’ Affiliations

Department of Microbiology, Dr. ALM PG IBMS, University of Madras, Taramani, Chennai, India
Govt. Hospital of Thoracic Medicine, Tambaram Sanatorium, Chennai, India
National Institute for Research in Tuberculosis (ICMR), Chetpet, Chennai, India


© Suthandhira et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.